CR Bard Touches New 52-Week High

Zacks

Shares of CR Bard Inc. (BCR) reached a new 52-week high of $150.13 on Apr 1, eventually closing at $149.25 on the same day. In fact, shares of this NJ-based manufacturer and distributor of healthcare products have been gaining momentum since it reported strong fourth-quarter and full-year 2013 results on Jan 30.

The company's share price has recorded a healthy return of around 50% over a year's time. Its long-term estimated EPS growth rate is pegged at 12.5%.

Strong Fourth-Quarter Performance

This Zacks Rank #2 (Buy) stock reported strong fourth-quarter results, reflecting year-over-year increases in both revenues and adjusted earnings. Adjusted earnings per share reached $1.42 in the quarter, beating the Zacks Consensus Estimate of $1.39 by 2.2%. Moreover, this company has delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 4.32%.

Revenues were $791.3 million, up 4% year over year, beating the Zacks Consensus Estimate by 1.52%. On a geographical basis, while domestic sales increased 4% to $517.7 million, international sales went up 3% to $273.6 million. International sales also increased 3%, on excluding the impact of foreign exchange. International sales growth was impacted by the sale of BCR's electrophysiology division affected during the quarter.

On a segment basis, worldwide revenues of Urology increased 3% year over year to $202.4 million. Roughly 200 basis points (bps) were added to global growth at this segment, contributed by the Rochester Medical acquisition in mid-November. Likewise, 11% revenue growth of PICC (peripherally inserted central catheter) with strong performance in both domestic and international markets along with a 2% rise in BCR's dialysis catheter business caused revenues from Oncology segment to increase 5% to $220.4 million.  

Management observed highest revenue growth of 16% in the Surgical Specialties segment in the fourth quarter, with domestic sales growth of 17% and international sales growth of 13%. BCR's research and development expenses climbed 220 bps to $70.4 million, reflecting higher investments pertaining to the company's strategic growth plan and the recent acquisitions.

During the fourth quarter, BCR repurchased around 1.4 million of the company's shares and returned over $800 million to shareholders in 2013.  

Estimates for BCR have been rising since its fourth-quarter earnings release. Over the last 90 days, the Zacks Consensus Estimate has risen 8.1% to $8.25 for 2014 and 6.8% to $9.14 for 2015.

Other Stocks to Consider

Some other stocks worth a look in the medical industry include Cardinal Health, Inc. (CAH), Becton, Dickinson and Company (BDX) and The Cooper Companies Inc. (COO). All these stocks carry a  Zacks Rank #2 (Buy).

Read the Full Research Report on BCR
Read the Full Research Report on BDX
Read the Full Research Report on CAH
Read the Full Research Report on COO


Zacks Investment Research

View Comments (0)